key: cord-0261141-s20pez9w authors: Taubner, B.; Peredo-Wende, R.; Ramani, A.; Singh, G.; Strle, K.; Cady, N. title: Rapid and Quantitative Detection of Human Antibodies Against the 2019 Novel Coronavirus SARS CoV2 and its Variants as a Result of Vaccination and Infection date: 2021-07-16 journal: nan DOI: 10.1101/2021.07.13.21260442 sha: 1f8b64f176bd11f3213b39ec08f6439f67f49dbc doc_id: 261141 cord_uid: s20pez9w Measuring the antibody response to 2019 SARS CoV2 is critical for diagnostic purposes, monitoring the prevalence of infection, and for gauging the efficacy of the worldwide vaccination effort COVID-19. In this study, a microchip-based grating coupled fluorescent plasmonic (GC-FP) assay was used to measure antibody levels that resulted from COVID-19 infection and vaccination. In addition, we measured the relative antibody binding towards antigens from variants CoV2 virus variants, strains B.1.1.7 (UK) and B.1.351 (S. African). Antibody levels against multiple antigens within the SARS CoV2 spike protein were significantly elevated for both vaccinated and infected individuals, while those against the nucleocapsid (N) protein were only elevated for infected individuals. GC-FP was effective for monitoring the IgG-based serological response to vaccination throughout the vaccination sequence, and could also resolve acute (within hours) increases in antibody levels. A significant decrease in antibody binding to antigens from the B.1.351 variant, but not B.1.1.7, was observed for all vaccinated subjects when measured by GC-FP as compared to the 2019 SARS CoV2 antigens. These results were corroborated by competitive ELISA assay. Collectively, the findings suggest that GC-FP is a viable, rapid, and accurate method for measuring both overall antibody levels to CoV2 and relative antibody binding to viral variants during infection or vaccination. The 2019 novel coronavirus, SARS CoV2 (COVID-19) has resulted in millions of deaths worldwide, and 50 has spurred the development of novel diagnostic strategies, detection technologies, and vaccination approaches. 51 Monitoring an individual's antibody responses to CoV2 antigens has become paramount from an 52 epidemiological perspective, but also as a means of determining the efficacy of vaccination. By measuring the levels of antibodies (primarily IgG) in human blood or other bodily fluids, an individual's prior infection 54 history, as well as their serological response to vaccination can be elucidated. Monitoring the stability and/or 55 decline of antibody levels over time is important in estimating how long individuals will retain immunity (1) . 56 Beyond assessing human serological response to infection or vaccination, it is important to understand how 57 an individual's immune system will respond to a growing number of novel CoV2 variants. A core area of 58 concern is mutations in the spike protein, which could interfere with antibody binding, and subsequently affect 59 the blockade (neutralization) of viral entry into human cells via the ACE2 receptor (2). This could ultimately . This is also an area of concern for variants emerging 64 in other regions, including Brazil and India (5, 6). This highlights the need for sensitive, specific, high-65 throughput assays to monitor antibody levels and predict effectiveness. 66 Multiplexed quantitative serological assays; allow both the determination of antibody levels in response 67 to infection and vaccination, and the ability to assess relative antibody neutralizing capacity, provide an 68 attractive diagnostic solution. Established methods of assessing antibody response to SARS CoV2 and its 69 variants include cell-based viral neutralization assays (2, 3, 7, 8) and competitive in vitro binding assays such as 70 ELISA (9, 10). Previously we demonstrated a grating-coupled fluorescent plasmonic (GC-FP) biosensor 71 platform for rapid (30 min), quantitative, multiplexed detection of human antibody response to both Lyme 72 disease and COVID-19 infection (11, 12). The GC-FP detection ratio (ratio of antibody binding to target 73 antigens vs. negative control proteins) for human serum and dried blood spot samples correlated strongly with 74 standard antibody testing approaches, including microsphere immunoassay (MIA) and ELISA (12). Notably, we 75 found that dried blood spot samples as well as more traditional blood serum samples could yield high sensitivity 76 and selectivity for diagnosing prior COVID-19 infection. 77 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2021. ; In the study presented here, we modified GC-FP detection microchips to include additional antigens from Nucleocapsid protein (N), the S1 fragment of the spike protein (S1), the extracellular domain of the 92 spike protein (S1S2), the receptor binding domain of the spike protein (RBD) for the 2019 SARS CoV2 virus, 93 S1 variant antigens, RBD variant antigens, and human serum albumin (HSA) were all obtained from Sino 94 Biological, Inc. (Table 1) Gold coated grating-coupled fluorescent plasmonic (GC-FP) biosensor chips were fabricated as 103 described our previous work (11, 12, 16). GC-FP chips were also printed as described previously (12). A map of 104 the protein/antigen spots is shown in the supplementary data, Figure S1 . October and December 2020 who enrolled in a study "Defining genetic and immune factors in COVID-19 111 severity." All patients had a positive RT-PCR test for CoV2 and were hospitalized due to severity of their 112 illness. Sera were processed on the day of collection and placed into -80C freezer until analyses. The study was 113 approved by the IRB at Albany Medical Center (Protocol # 5929). (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2021. ; sequence, including pre-vaccination, at the second dose, and two weeks after the second dose, 3) vaccinated (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2021. ; https://doi.org/10.1101/2021.07.13.21260442 doi: medRxiv preprint GC-FP diagnostic ratio data and percent binding inhibition data for the ACE2 competitive assay were 149 analyzed using GraphPad Prism 8.0 software (ROC analysis, correlation, and statistical analysis). CoV2 spike protein antigens (S1, S1S2, RBD) and the nucleocapsid protein (N). As we described in previous 157 work (12), the GC-FP diagnostic ratio provides a quantitative measure of antibody levels and correlates well 158 with established serological techniques such as MIA and ELISA. In the current work, antibody levels in 159 vaccinated individuals were significantly elevated for all spike antigens (Mann-Whitney, p < 0.0001), with 160 highest mean increase in antibody levels observed for the S1 and RBD antigens (supplementary information, 161 Figure S2A ). A nominal increase in antibody levels was also observed against the S1S2 antigen and N protein, 162 but reactivity to these antigens was significantly less than for S1 and RBD. Receiver operator characteristic 163 (ROC) analysis on these data (supplementary information, Figure S2B ) showed that antibody levels against S1 164 were diagnostic for vaccination status with 61% sensitivity and 100% specificity, while levels against RBD 165 were diagnostic with 80% sensitivity and 100% specificity. Antibody levels for S1S2 and N resulted in low area 166 under the curve (AUC) results from the ROC analysis and were considered insufficient for diagnostic purposes. Because all three vaccines should only elicit immunological response to the SARS CoV2 spike antigen, the lack 168 of a diagnostic antibody response for the N protein was expected. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2021. ; Dried blood samples were also tested using GC-FP for ten (10) individuals throughout their vaccination 179 sequence with the Pfizer-BioNTech vaccine (pre-vaccine, at the time of the 2 st dose, and 2 weeks after 2 nd 180 dose). Antibody levels (as determined by GC-FP detection ratio) were significantly higher for the S1, S1S2, 181 and RBD antigens at both the time of the 2 nd dose and 2 weeks after the second dose ( Figure 1 ). As expected, 182 antibodies against the N antigen were not detected at any of these time points, since all three vaccines utilize the 183 spike antigen (and not the N antigen) to induce immune response. 184 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2021. ; https://doi.org/10.1101/2021.07.13.21260442 doi: medRxiv preprint GC-FP was also used to detect antibody levels against SARS CoV2 antigens and antigens from variants (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. higher antibody levels against S1 and RBD antigens. Acutely infected (hospitalized) individuals had elevated 210 antibody levels for S1S2 and N antigens, while non-hospitalized patients only showed increased antibody levels 211 against N. Notably, individuals who were vaccinated after prior infection had the highest mean antibody levels 212 against S1 and RBD. This is consistent with the fact that these individuals were effectively exposed to the spike Uninfected samples were collected prior to vaccination, from individuals who reported no prior COVID-19 symptoms, 218 and tested negative via PCR and/or antibody testing (n = 42). Other samples were from PCR confirmed COVID-19 219 positive subjects who were hospitalized (n = 3), PCR confirmed COVID-19 positive subjects who were not hospitalized 220 CoV2 (n = 5), and previously COVID-19 positive subjects who received subsequent vaccination (n = 9). Samples were 221 also collected from subjects who were at least 2 weeks past full vaccination with Pfizer-BioNTech (n = 17), Moderna (n = 222 8), or 2 weeks after receiving the Johnson & Johnson vaccine (n = 9). One-way ANOVA followed by Dunnett's multiple 223 comparison testing was performed (*p = 0.03, ** p = 0.002, *** p = 0.0002, **** p < 0.0001). Figure S3 ). To account for these differences, 227 and to elucidate relative antibody binding levels to variant antigens vs. 2019 SARS CoV2 antigens, the fold-228 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2021. ANOVA followed by Dunnett's multiple comparison testing was performed (*p = 0.03, ** p = 0.002, *** p = 0.0002, 240 **** p < 0.0001). 241 242 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2021. ; https://doi.org/10.1101/2021.07.13.21260442 doi: medRxiv preprint To determine if these results were due to differences in antibody affinity towards variant vs. 2019 SARS (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 282 We previously demonstrated that GC-FP is a rapid and accurate technique for detection of antibodies that 283 result from COVID-19 infection (12). In the current study, we extended this work to show that GC-FP can 284 measure the level of antibodies resulting from vaccination, and that it can quantitatively measure the increase in The results of the present study, together with our previous demonstration of GC-FP for COVID-19 301 antibody detection (12) compare favorably to similar studies using multiplexed, array-based techniques. Using a (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2021. ; https://doi.org/10.1101/2021.07.13.21260442 doi: medRxiv preprint While this approach enables extremely high throughput, it is limited in the number of target antigens that can be 307 implemented, and requires complicated printing of human blood samples to prepare detection chips. In the work presented here, we have demonstrated that GC-FP based, multiplexed detection of antibody 309 binding from human blood is a useful tool for determining an individual's response to vaccination and the (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 16, 2021. ; https://doi.org/10.1101/2021.07.13.21260442 doi: medRxiv preprint 320 Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y 327 variants by BNT162b2 vaccine-elicited sera BNT162b2 mRNA 329 COVID-19 vaccine induces antibodies of broader cross-reactivity than natural infection but recognition of mutant 330 viruses is up to 10-fold reduced Covid-19: What new variants are emerging and how are they being investigated? Covid-19: UK cases of variant from India rise by 160% in a week A high-334 throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated 337 blockage of ACE2-spike protein-protein interaction Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from 340 hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays 2021. A highly specific and sensitive serological assay detects SARS-CoV-2 346 antibody levels in COVID-19 patients that correlate with neutralization A fluorescent 348 plasmonic biochip assay for multiplex screening of diagnostic serum antibody targets in human Lyme disease Multiplexed detection and quantification of human antibody response to COVID-19 infection using a plasmon 352 enhanced biosensor platform Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Efficacy and Safety of the mRNA-361 1273 SARS-CoV-2 Vaccine S Vaccine against Covid-19 Rapid and multiplexed detection of Lyme disease 368 using a grating coupled-fluorescent plasmonics (GC-FP) biosensor platform Quantification of 371 antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates